LRMR Larimar Therapeutics
- 9.020
- +1.020+12.75%
Larimar Therapeutics News
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hamilton Thomas Edward
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Truitt Joseph
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director SHERMAN JEFFREY W
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director LEFF JONATHAN S
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director THOMAS FRANK E
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | EFFECT: Others
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | S-3: Registration statement for specified transactions by certain issuers
Larimar Therapeutics | 10-Q: Quarterly report
Larimar Therapeutics | 8-K: Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
Larimar Therapeutics | ARS: Annual Report to Security Holders
Larimar Therapeutics | DEF 14A: Definitive information statements
Larimar Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Larimar Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Deerfield Management Company, L.P.(33.32%),James E. Flynn(33.32%), etc.
Larimar Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Larimar Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Larimar Therapeutics | 10-K: Annual report
Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
Analysis
Price Target
No Data
